InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
wesley_ PremiumMember
01/10/19 11:49 AM
profile icon
jfk Free
12/27/18 10:38 PM
profile icon
ireadthefins Free
12/11/18 8:39 AM
profile icon
TrendTrade2016 Free
11/17/18 5:50 AM
profile icon
barknbud Free
11/16/18 11:06 AM
profile icon
TrendTrade2016 Free
11/16/18 10:20 AM
profile icon
TrendTrade2016 Free
11/16/18 8:25 AM
profile icon
Dennisb68 PremiumMember
11/14/18 10:26 AM
profile icon
ireadthefins Free
11/08/18 7:13 AM
profile icon
derkampfer Free
11/07/18 11:59 PM
profile icon
ireadthefins Free
11/07/18 9:55 AM
profile icon
Dennisb68 PremiumMember
11/01/18 4:38 PM
profile icon
derkampfer Free
10/29/18 9:16 AM
profile icon
Dennisb68 PremiumMember
10/28/18 7:37 PM
profile icon
barknbud Free
10/28/18 5:45 PM
profile icon
ireadthefins Free
10/27/18 3:45 PM
profile icon
derkampfer Free
10/26/18 1:37 PM
profile icon
TrendTrade2016 Free
10/26/18 5:46 AM
profile icon
ireadthefins Free
10/26/18 1:11 AM
profile icon
derkampfer Free
10/26/18 12:36 AM
profile icon
ireadthefins Free
10/25/18 11:52 PM
profile icon
TrendTrade2016 Free
10/25/18 4:09 PM
profile icon
barknbud Free
10/22/18 9:06 AM
profile icon
Dennisb68 PremiumMember
10/17/18 3:46 PM
profile icon
Stratdan Free
04/11/18 7:12 AM
profile icon
Stratdan Free
03/18/18 7:37 AM
profile icon
ClayTrader Free
01/30/18 5:19 PM
profile icon
Atlanta1 Free
01/30/18 1:24 PM
profile icon
ClayTrader Free
10/19/17 5:24 PM
profile icon
Hercules1 Free
10/19/17 2:24 PM
profile icon
Hercules1 Free
10/19/17 1:00 PM
profile icon
Hercules1 Free
10/19/17 12:43 PM
profile icon
Hercules1 Free
10/19/17 11:10 AM
profile icon
Awl416 Free
10/19/17 9:55 AM
profile icon
Awl416 Free
10/19/17 9:42 AM
profile icon
wiltonio Free
03/29/17 6:15 AM
profile icon
goingforittoday Free
02/28/17 10:32 AM
profile icon
BrazenBull Free
04/05/16 1:21 AM
profile icon
MasterBidder Free
12/17/15 3:02 PM
profile icon
ronk Free
12/06/15 1:19 PM
profile icon
ronk Free
12/04/15 7:29 PM
profile icon
Stock Guy777 Free
12/04/15 6:57 PM

Imprimis Pharmaceuticals Inc (IMMY) RSS Feed

Followers
59
Posters
221
Posts (Today)
0
Posts (Total)
3167
Created
07/01/11
Type
Free
Moderators
Imprimis Pharmaceuticals, Inc.
 
NASDAQ
: IMMY

Oct 22, 2015. Last month, Turing Pharmaceuticals LLC, the sole supplier of Daraprim, increased the price of this prescription drug from $13.50 per tablet to a reported $750.00 per tablet. The FDA-approved label for Daraprim indicates that it is prescribed for toxoplasmosis and other types of infections. Toxoplasmosis can be of major concern for patients with weakened immune systems such as patients with HIV/AIDS, pregnant women and children. According to the Centers for Disease Control and Prevention, pyrimethamine works to block folic acid synthesis in the parasite T. gondii, the cause of toxoplasmosis, and leucovorin helps to reverse the negative effects on bone marrow caused by this mechanism of action.

Imprimis is now offering customizable compounded formulations of pyrimethamine and leucovorin in oral capsules starting as low as $99.00 for a 100 count bottle, or at a cost of under a dollar per capsule. Compounded medications may be appropriate for prescription when a commercially-available medicine does not meet the specific needs of a patient. For ordering information, please visit www.imprimiscares.com.

Mark L. Baum, CEO of Imprimis stated, "It is indisputable that generic drug prices have soared recently. While we have seen an increase in costs associated with regulatory compliance, recent generic drug price increases have made us concerned and caused us to take positive action to address an opportunity to help a needy patient population. While we respect Turing's right to charge patients and insurance companies whatever it believes is appropriate, there may be more cost-effective compounded options for medications, such as Daraprim, for patients, physicians, insurance companies and pharmacy benefit managers to consider. This is not the first time a sole supply generic drug – especially one that has been approved for use as long as Daraprim – has had its price increased suddenly and to a level that may make it unaffordable. In response to this recent case and others that we will soon identify, Imprimis is forming a new program called Imprimis Cares which is aligned to our corporate mission of making novel and customizable medicines available to physicians and patients today at accessible prices."

Mr. Baum added, "Today, some drug prices are simply out of control and we believe we may be able to help control costs by offering compounded alternatives to several sole source legacy generic drugs. Imprimis Cares and its team of compounding pharmacists will work with physicians and their patients to ensure they have affordable access to the medicines they need from the over 7,800 generic FDA-approved drugs. Imprimis Cares, available in all 50 states, will work with all third party insurers, pharmacy benefit managers and buying groups to offer its patient specific customizable compounded drug formulations at prices that ensure accessibility and that provide a reasonable profit for Imprimis. We are here to serve our patients and their physicians. We believe that when we do a great job serving our customers, our shareholders will also benefit."

Imprimis' finished compounded drug formulations do not have an FDA-approval label for recommended use. Imprimis compounded formulations are not FDA approved and may only be prescribed pursuant to a physician prescription for an individually identified patient consistent with federal and state laws governing compounded drug formulations.

Daraprim® is a registered trademark of Turing Pharmaceuticals LLC. Imprimis is not affiliated with Turing Pharmaceuticals LLC nor Daraprim®. Daraprim® is an FDA-approved drug. Please consult with your physician regarding which prescription options are most suitable for your specific needs.

ABOUT IMPRIMIS PHARMACEUTICALS

San Diego-based Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) is a national leader in the development, production and dispensing of novel compounded pharmaceuticals. The company's business primarily consists of four therapeutic segments including ophthalmology, urology, sinus and integrative medicine. Imprimis dispenses compounded pharmaceuticals in all 50 states from four facilities located in California, Texas, New Jersey and Pennsylvania. For more information about Imprimis, please visit the corporate website at www.ImprimisPharma.com.




http://www.imprimispharma.com/


 
Common stock outstanding after the offering       8,391,172

Cash and cash equivalents                                            18,059,285
 
   
   
 

MORE INFORMATION WILL BE ADDED TO THIS INTRO MESSAGE WHEN MADE AVAILABLE. THANKS FOR YOUR PATIENCE.

 
Most Liked Posts
(Last 30 Days)
IMMY Latest News
  • No Recent News Available for this company!
Most Liked Posts
(Last 30 Days)
New Post